Oncology Institute Inc (TOI) concluded trading on Thursday at a closing price of $3.65, with 4.34 million shares of worth about $15.85 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 886.75% during that period and on July 17, 2025 the price saw a gain of about 13.00%. Currently the company’s common shares owned by public are about 88.93M shares, out of which, 45.65M shares are available for trading.
Stock saw a price change of 27.18% in past 5 days and over the past one month there was a price change of 49.59%. Year-to-date (YTD), TOI shares are showing a performance of 630.00% which increased to 1081.23% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.13 but also hit the highest price of $3.50 during that period. The average intraday trading volume for Oncology Institute Inc shares is 1.99 million. The stock is currently trading 41.09% above its 20-day simple moving average (SMA20), while that difference is up 33.49% for SMA50 and it goes to 189.25% higher than SMA200.
Oncology Institute Inc (NASDAQ: TOI) currently have 88.93M outstanding shares and institutions hold larger chunk of about 14.85% of that.
The stock has a current market capitalization of $335.49M and its 3Y-monthly beta is at 0.04. It has posted earnings per share of -$0.70 in the same period. It has Quick Ratio of 1.59 while making debt-to-equity ratio of 20.18. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TOI, volatility over the week remained 11.05% while standing at 10.30% over the month.
Stock’s fiscal year EPS is expected to rise by 34.51% while it is estimated to increase by 80.65% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by B. Riley Securities on July 16, 2025 offering a Buy rating for the stock and assigned a target price of $6 to it. Coverage by BTIG Research stated Oncology Institute Inc (TOI) stock as a Buy in their note to investors on May 15, 2025, suggesting a price target of $7 for the stock. On February 26, 2024, Jefferies Resumed their recommendations, while on September 14, 2022, Guggenheim Initiated their ratings for the stock with a price target of $7. Stock get a Buy rating from Jefferies on August 15, 2022.
